ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for Vitreomacular Adhesion
Highly significant trial result (p=0.003) demonstrates the potential of microplasmin in the treatment of retinal disease
21-Apr-2010 -
ThromboGenics NV announced that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint (p=0.003). The trial, TG-MV-006, recruited a total of 326 patients in the U.S. A second Phase III study with microplasmin, TG-MV-007, which ...
adhesion
eye disease
focal vitreomacular adhesion
+5